1. Increase myocardial blood flow and have a significant protective effect on myocardial ischemia. 2. Lower blood pressure and protect target organs. 3. Lower serum cholesterol and triglycerides. 4. Improve the body's immune function and delay aging.

This product is a derivative of retinoic acid, with a structural formula similar to all-trans retinoic acid, and a mechanism of action similar to 13-cis retinoic acid and aromatic retinoic acid; but the side effects are milder than all-trans retinoic acid. Oral administration can regulate and control the differentiation and growth of epithelial cells, resulting in keratinization, reduce sebum secretion, inhibit the keratinization process of keratinocytes, restore abnormal keratinization to normal, inhibit the growth of Propionibacterium acnes, and has immune regulation and anti-inflammatory effects.

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. Rifampicin has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. Rifampicin also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis. Bacteria have cross-resistance to rifamycin antibiotics. Rifampicin binds firmly to the β-subunit of DNA-dependent RNA polymerase, inhibiting the synthesis of bacterial RNA and preventing the enzyme from connecting to DNA, thereby blocking the RNA transcription process and stopping the synthesis of DNA and protein.

Erythromycin stearate belongs to the macrolide antibiotics, and has antibacterial activity against Staphylococcus, various groups of Streptococcus and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial activity against various anaerobic bacteria except Bacteroides fragilis and Fusobacterium; it also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis. Erythromycin stearate is only effective against bacteria that actively divide.

1. Stimulate the pancreatic islet beta cells to secrete insulin, the prerequisite is that the islet beta cells have a certain ability to synthesize and secrete insulin; 2. By increasing the level of portal vein insulin or directly acting on the liver, inhibiting liver glycogenolysis and gluconeogenesis, the liver produces and outputs less glucose; 3. It may increase the sensitivity of extrapancreatic tissue to insulin and the utilization of sugar (probably mainly through post-receptor effects), so the overall effect is to reduce fasting blood sugar and postprandial blood sugar. In addition, it also has an antidiuretic effect, which can reduce the clearance of free water. In patients with partial diabetes insipidus, it can enhance the residual antidiuretic hormone effect.